The pharmaceutical industry is one of the major players in the healthcare sector. Governments across Europe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending due to the increasing pressure between the demands of the EU, national governments and regional authorities.

As healthcare budgets are continuously rising in Europe, governments implement a wide variety of policies to control them with the help of different public regulatory bodies that are involved in pharmaceutical coverage decisions across Europe.

At a global scale, pharmaceutical market was worth around $300 billion in 2015, according to World Health Organization, and it is expected to surpass $400 billion by 2018.

International collaboration among HTA and regulatory bodies can promote knowledge exchange, efficiency of information production and prepare developing systems for new challenges.

The upcoming 2017 Market Access, Pricing and Reimbursement Global Congress Europe will present a dynamic approach to key trends and insights on market access, health technology assessment, real world data, patient access, pricing and reimbursement on the current European landscape.